Vol. 69 No. 1 (2023), REVIEWS

Vol. 69 No. 1 (2023)

Prospects for the application of microRNAs (miR-371, miR-302, miR-372, miR-367) as biomarkers in patients with germ cell tumors

REVIEWS

https://doi.org/10.37469/0507-3758-2023-69-1-24-29

Published 07.03.2023

Valentina Andreevna Zagoruiko ⁺⁻
Alexander Konstantinovich Nosov
Margarita Sergeevna Knyazeva
Nikita Andreevich Shchekuteev
Artur Yurevich Malygin
Dmitry Alekseevich Savkin
Svetlana Anatolevna Protsenko

Valentina Andreevna Zagoruiko

ФГБУ "НМИЦ онкологии им.Н.Н.Петрова"

https://orcid.org/0000-0001-7508-8383

Alexander Konstantinovich Nosov

Margarita Sergeevna Knyazeva

Nikita Andreevich Shchekuteev

Artur Yurevich Malygin

Dmitry Alekseevich Savkin

Svetlana Anatolevna Protsenko

pdf (Русский)

Keywords

microRNA
tumor markers
biomarker
germ cell tumors

How to Cite

Zagoruiko , V. A., Nosov, A. K., Knyazeva , M. S., Shchekuteev , N. A., Malygin , A. Y., Savkin , D. A., & Protsenko , S. A. (2023). Prospects for the application of microRNAs (miR-371, miR-302, miR-372, miR-367) as biomarkers in patients with germ cell tumors. Voprosy Onkologii, 69(1), 24–29. https://doi.org/10.37469/0507-3758-2023-69-1-24-29

Abstract

This review presents the latest clinical studies data exploring microRNA that can have a potential value as biological marker in patients with germ cell tumors.

Common tumor markers in the diagnosis and treatment of patients with germ cell tumors are not sensitive and not specific enough. This induced studies and search for new tumor markers. One of such biomarkers is microRNA. These are single-stranded RNAs that inhibit protein synthesis or initiate mRNA degradation.

Current clinical studies suggest that these molecules can be used in clinical practice and can potentially influence clinical decision-making in the treatment of patients with germ cell tumors.

https://doi.org/10.37469/0507-3758-2023-69-1-24-29

pdf (Русский)

References

Cancer Stat Facts: Testicular Cancer [Internet]. National Cancer Institute. [cited 2022 Mar 1]. Available from: https://seer.cancer.gov/statfacts/html/testis.html.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590.

Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol. 2016;13(12):715-25. doi: 10.1038/nrurol.2016.170.

Murray MJ, Coleman N. A new generation of biomarkers for malignant germ cell tumours. Nat Rev Urol. 2012;9(6):298-300. doi: 10.1038/nrurol.2012.86.

Croce CM, Calin GA. MiRNAs, cancer, and stem cell division. Cell. 2005;122(1):6-7. doi: 10.1016/j.cell.2005.06.036.

Belge G, Grobelny F, Radtke A. et al. Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. J Cancer Res Clin Oncol. 2021;147(2):435. doi: 10.1007/s00432-020-03429-x.

Dieckmann KP, Spiekermann M, Balks T. et al. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer. 2012;107(10): 1754-60. doi: 10.1038/bjc.2012.469.

Belge G, Dieckmann KP, Spiekermann M. Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors? Eur Urol. 2012;61(5):1068-9. doi: 10.1016/j.eururo.2012.02.037.

Dieckmann K-P, Spiekermann M, Balks T. et al. MicroRNA miR-371a-3p - A novel serum biomarker of testicular germ cell tumors: Evidence for specificity from measurements in testicular vein blood and in neoplastic hydrocele fluid. Urol Int. 2016;97(1):76-83. doi: 10.1159/000444303.

Pelloni M, Coltrinari G, Paoli D. et al. Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients. Endocrine. 2017;57(3):518-27. doi: 10.1007/s12020-016-1150-z.

Syring I, Bartels J, Holdenrieder S. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J Urol. 2015;193(1):331-7. doi: 10.1016/j.juro.2014.07.010.

Spiekermann M, Belge G, Winter N. et al. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker. Andrology. 2015;3(1):78-84. doi: 10.1111/j.2047-2927.2014.00269.x.

Van Agthoven T, Looijenga LHJ. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test). Oncotarget. 2016;8(35):58037-49. doi: 10.18632/oncotarget.10867.

Dieckmann K-P, Radtke A, Spiekermann M, et al. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. Eur Urol. 2017;71(2):213-20. doi: 10.1016/j.eururo.2016.07.029.

Gillis AJM, Rijlaarsdam MA, Eini R, et al. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Mol Oncol. 2013;7(6):1083-92. doi: 10.1016/j.molonc.2013.08.002.

Mørup N, Rajpert-De Meyts E, Juul A, et al. Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up―A Copenhagen Experience. Cancers (Basel). 2020;12(3):759. doi: 10.3390/cancers12030759.

Dieckmann K-P, Radtke A, Geczi L, et al. Serum levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: Results of a prospective multicentric study. J Clin Oncol. 2019;37(16):1412-23. doi: 10.1200/JCO.18.01480.

Nappi L, Thi M, Lum A, et al. Developing a highly specific biomarker for germ cell malignancies: Plasma miR371 expression across the germ cell malignancy spectrum. J Clin Oncol. 2019;37(33):3090-8. doi: 10.1200/JCO.18.02057.

Badia RR, Abe D, Wong D, et al. Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor management. J Urol. 2021;205(1):137-44. doi: 10.1097/JU.0000000000001337.

Leão R, Albersen M, Looijenga LHJ, et al. Circulating MicroRNAs, the next-generation serum biomarkers in testicular germ cell tumours: A systematic review. Eur Urol. 2021;80(4):456-66. doi: 10.1016/j.eururo.2021.06.006.

Mego M, Agthoven T, Gronesova P, et al. Clinical utility of plasma miR‐371a‐3p in germ cell tumors. J Cell Mol Med. 2019;23(2):1128. doi: 10.1111/jcmm.14013.

Lobo J, Gillis AJM, van den Berg A, et al. Identification and validation model for informative liquid biopsy-based microRNA biomarkers: Insights from germ cell tumor in vitro, in vivo and patient-derived data. Cells. 2019;8(12):1637. doi: 10.3390/cells8121637.

Radtke A, Hennig F, Ikogho R, et al. The novel biomarker of germ cell tumours, Micro-RNA-371a-3p, has a very rapid decay in patients with clinical stage 1. Urol Int. 2018;100(4):470. doi:10.1159/000488771.

Dieckmann K-P, Simonsen-Richter H, Kulejewski M, et al. Serum tumour markers in testicular germ cell tumours: Frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment. Biomed Res Int. 2019; 75(4):376. doi:10.1155/2019/5030349.

Van Agthoven T, Eijkenboom WMH, Looijenga LHJ. MicroRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. Cell Oncol (Dordr). 2017;40(4):379-88. doi: 10.1007/s13402-017-0333-9.

Anheuser P, Radtke A, Wülfing C, et al. Serum levels of MicroRNA371a-3p: A highly sensitive tool for diagnosing and staging testicular germ cell tumours: A clinical case series. Urol Int. 2017;99(1):98. doi: 10.1159/000477446.

Lobo J, Leão R, Gillis AJM, et al. Utility of serum miR-371a-3p in predicting relapse on surveillance in patients with clinical stage i testicular germ cell cancer. Eur Urol Oncol. 2021;4(3):483-91. doi: 10.1016/j.euo.2020.11.004.

Murray MJ, Halsall DJ, Hook CE. Identification of microRNAs From the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am J Clin Pathol. 2011;135(1):119-25. doi: 10.1309/AJCPOE11KEYZCJHT.

Leão R, van Agthoven T, Figueiredo A, et al. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. J Urol. 2018;200(1):126-35. doi: 10.1016/j.juro.2018.02.068.

Rosas Plaza XR, van Agthoven T, Meijer C, et al. MiR-371a-3p, miR-373-3p and miR-367-3p as serum biomarkers in metastatic testicular germ cell cancers before, during and after chemotherapy. Cells. 2019;8(10). doi: 10.3390/cells8101221.

Shen H, Shih J, Hollern DP, et al. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep. 2018;23(11):3392-406. doi: 10.1016/j.celrep.2018.05.039.

Radtke A, Cremers J-F, Kliesch S, et al. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p? J Cancer Res Clin Oncol. 2017;143(11):2383-92. doi: 10.1007/s00432-017-2490-7.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.